Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian association of endocrinologists expert consensus document (2015)

Diabetes Mellitus

Volumn 18, Issue 1, 2015, Pages 5-23

  Dedov, I I ^a   Shestakova, M V ^a,e   Ametov, A S ^b   Antsiferov, M B ^c   Galstyan, G R ^a,e   Mayorov, A Y ^a,e   Mkrtumyan, A M ^d   Petunina, N A ^e   Sukhareva, O Y ^a  

^a ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^b Russian Academy of Post Graduate Medical Education   (Russian Federation)

^c MOSCOW HEALTHCARE DEPARTMENT   (Russian Federation)

^d A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^e I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Antidiabetic therapy; Consensus; Glucoselowering therapy; Guidelines; Russian association for endocrinologists; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERGLYCEMIC AGENT; INSULIN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CONSENSUS; DRUG BIOAVAILABILITY; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG SAFETY; ENDOCRINOLOGIST; HUMAN; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT CENTERED APPROACH; RUSSIAN (PEOPLE);

EID: 84929627871     PISSN: 20720351     EISSN: 20720378     Source Type: Journal    
DOI: 10.14341/DM201515-23     Document Type: Article

References (26)

1. Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. doi: 10.14341/DM20151S1-112
2. Dedov II, Shestakova MV, Ametov AS, et al. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;14(4):6-17. doi: 10.14341/2072-0351-5810
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine practice. 2009;15(6):540-559. doi: 10.4158/EP.15.6.540
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-442. doi: 10.1007/s00125-014-3460-0
5. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008;358(24):2545-2559. doi: 10.1056/NEJMoa0802743
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England journal of medicine. 2009;360(2):129-139. doi: 10.1056/NEJMoa0808431
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
8. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008;358(24):2560-2572. doi: 10.1056/NEJMoa0802987
9. Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1-120. doi: 10.14341/DM20131S1-121
10. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mildto-Moderate Renal Insufficiency. Diabetes care. 2011;34(6):1431-1437. doi: 10.2337/dc10-2361
11. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52(3):741-750.
12. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695-1704. doi: 10.2337/db05-1602
13. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine. 2013;369(14):1317-1326. doi: 10.1056/NEJMoa1307684
14. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine. 2013;369(14):1327-1335. doi: 10.1056/NEJMoa1305889
15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine reviews. 2012;33(2):187-215. doi: 10.1210/er.2011-1052
16. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessent. The New England journal of medicine. 2014;370(9):794-797. doi: 10.1056/NEJMp1314078
17. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. British journal of pharmacology. 2003;140(1):123-132. doi: 10.1038/sj.bjp.0705397
18. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270-2276. doi: 10.2337/diabetes.48.12.2270
19. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and metaanalysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes care. 2007;30(2):389-394. doi: 10.2337/dc06-1789
20. U.S. Food and Drug Administration. FDA News Release (25-nov-2013): FDA requires removal of certain restrictions on the diabetes drug Avandia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
21. Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(3):493-504. doi: 10.1007/s00125-014-3456-9
22. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014;8:1335-1380. doi: 10.2147/DDDT.S50773
23. American Diabetes Asosiation. Approaches to Glycemic Treatment. Diabetes care. 2015;38(Supplement 1):S41-S48. doi: 10.2337/dc15-S010
24. Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes care. 2014;37(7):1815-1823. doi: 10.2337/dc13-3055
25. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathwys and review of ongoing outcome trials. Diabetes & vascular disease research. 2015;12(2):90-100. doi: 10.1177/1479164114559852
26. Dedov II, Shestakova MV, Abusuev SA, Valeeva FV, Verbovoy AF, Galstyan GR, et al. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010;13(5):9-16. doi: 10.14341/2072-0351-6049